

Vitrolife's CEO has purchased shares

Vitrolife's CEO Thomas Axelsson has today acquired 12,000 shares worth 2,124,000 MSEK. The total holdings of shares amount to 25,000.

The transaction will be reported to The Swedish Financial Supervisory Authority (Finansinspektionen) according to current regulations.

Gothenburg, October 28, 2022
VITROLIFE AB (publ)
Thomas Axelsson, CEO

Contact persons:

Thomas Axelsson, CEO, tel: +46 31 721 80 01
Patrik Tolf, CFO, tel: +46 31 766 90 21

Vitrolife Group is a global provider of medical devices and genetic services. Based on science and advanced research capabilities, we develop services and products for personalized genetic information and medical device products. We are supporting our customers by improving their clinical practice and the outcome of the patient's fertility treatment. Currently, we are approximately 1,100 people worldwide, headquartered in Gothenburg, Sweden.

Vitrolife Group's products and services are available in more than 110 countries, through our own presence in 30 countries and a network of distributors. We are a sustainable market leader and aim to be the preferred partner to the IVF-clinics by providing superior products and services with the vision to fulfil the dream of having a baby. The Vitrolife AB (publ) is listed on Nasdaq Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg. Corporate ID number 556354-3452. Tel: +46 31 721 80 00. Fax: +46 31 721 80 99. E-mail: info@vitrolife.com.
Website: www.vitrolife.com

This information is information that Vitrolife AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 10.45 am CET on October 28, 2022.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.